<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01360749</url>
  </required_header>
  <id_info>
    <org_study_id>ISD-LAM-2010-01</org_study_id>
    <nct_id>NCT01360749</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lambdalina (Lidocaine Cream) Versus Placebo as an Anesthetic for Laser Hair Removal</brief_title>
  <official_title>Multicentre, Double-Blind Trial to Evaluate the Efficacy and Safety of Lambdalina vs Placebo as an Anesthetic for Laser Hair Removal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ISDIN</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ISDIN</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, randomized, placebo-controlled trial to assess the efficacy of Lambdalina
      (lidocaine cream) in reducing pain associated with laser hair removal in women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in pain intensity (Pain Visual Analogue Scale) associated to laser hair removal from baseline to the end of laser hair removal session (primary endpoint)</measure>
    <time_frame>30 minutes after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessments including AEs and SAEs</measure>
    <time_frame>48 hours after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Local Anesthesia</condition>
  <arm_group>
    <arm_group_label>Lambdalina and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive lambdaline (lidocaine cream 40 mg/g) in Left Lower Extremity and placebo in Right Lower Extremity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and lambdalina</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive placebo in Left Lower Extremity and lambdaline (lidocaine cream 40 mg/g) in Right Lower Extremity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lambdalina® (Lidocaine 4% cream)</intervention_name>
    <description>Lambdaline dose: 2 g for 10 cm2.</description>
    <arm_group_label>Lambdalina and placebo</arm_group_label>
    <arm_group_label>Placebo and lambdalina</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo dose: 2 g for 10 cm2.</description>
    <arm_group_label>Lambdalina and placebo</arm_group_label>
    <arm_group_label>Placebo and lambdalina</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women ≥ 18 and ≤ 65 years old.

          2. Laser hair removal treatment session in the legs in the area from the knee to the
             ankle (first or second application).

          3. Able of accomplishing the study's requirements.

          4. Negative result in the pregnancy test.

          5. Sterile or surgically sterilized women (hysterectomy, tubal ligation) or using
             adequate contraceptive methods.

          6. Written informed consent prior to inclusion in the trial.

        Exclusion Criteria:

        - General exclusion criteria:

          1. Pregnant or breastfeeding.

             - Current or previous medical conditions:

          2. Skin type 5 or 6 or a history of photosensitivity.

          3. Cardiovascular diseases such as unstable angina, or severe heart failure (New York
             Heart Association III or IV).

          4. Neuropathy or paresthesia.

          5. History of hepatic failure.

          6. Autoimmune diseases.

          7. Allergies to peanuts and/or soy and/or any components of the formulation.

          8. Use or dependence on prohibited substances.

          9. Other contraindications specified in the summary of product characteristics.

             - Current or previous concomitant medications:

         10. Any anesthetic or analgesic treatment during 2 hours prior of study entry.

         11. Concomitant treatment with antiarrhythmic drugs of class I (eg. tocainide, mexiletine)
             or class III (eg. amiodarone, sotalol), anticoagulants, anti-platelet aggregating
             and/or beta-blockers.

         12. Active wounds or irritations in the area to be treated.

         13. Topical treatment with corticosteroids or other topical agent in the area to be
             studied.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Campo Voegeli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Clínica Dermatológica Campo De Felipe, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Serafín Fernández, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Dermatológica Láser, Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Campo Voegeli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Dermatológica Campo De Felipe, Barcelona, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clínica Dermatológica Campo De Felipe</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Dermatológica Láser</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2011</study_first_submitted>
  <study_first_submitted_qc>May 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2011</study_first_posted>
  <last_update_submitted>April 12, 2012</last_update_submitted>
  <last_update_submitted_qc>April 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain management</keyword>
  <keyword>Lidocaine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

